A5074778675- Schizophrenia research and treatment
- Attention Deficit Hyperactivity Disorder
- Pharmaceutical studies and practices
- Treatment of Major Depression
- Health Systems, Economic Evaluations, Quality of Life
- Bipolar Disorder and Treatment
- Mental Health and Psychiatry
- Epilepsy research and treatment
- Psychosomatic Disorders and Their Treatments
- Family Caregiving in Mental Illness
- Child Nutrition and Feeding Issues
- Pharmaceutical Practices and Patient Outcomes
- Obsessive-Compulsive Spectrum Disorders
- Pharmacological Effects and Toxicity Studies
- Cardiac electrophysiology and arrhythmias
- Mental Health Treatment and Access
- Parkinson's Disease and Spinal Disorders
- Healthcare Decision-Making and Restraints
- Autism Spectrum Disorder Research
- Child and Adolescent Psychosocial and Emotional Development
- Botulinum Toxin and Related Neurological Disorders
- Parkinson's Disease Mechanisms and Treatments
- Pain Management and Placebo Effect
- Medication Adherence and Compliance
- Neurotransmitter Receptor Influence on Behavior
Janssen (Germany)
2009-2019
Johnson & Johnson (Germany)
2012-2016
Janssen (Belgium)
2008-2015
Ruhr University Bochum
1997
Relapse and acute exacerbation are common in schizophrenia may impact treatment response outcome. Evidence is conflicting respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics relapse prevention. This randomized controlled study assessed the efficacy paliperidone palmitate for prevention.Eligible patients with a recent diagnosis (within 1-5 years) were 1:1 (n=376) or monotherapy (n=388) entered 2-week initial phase. Patients who met predefined...
In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored patients acute symptoms of schizophrenia following switching from previously unsuccessful oral antipsychotics. This pragmatic was conducted a large, more representative sample the general population compared to randomized controlled pivotal trials, specifically mimic...
To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic (>3 years).Post hoc analysis a prospective, interventional, single-arm, multicentre, open-label, 6-month study performed 233 360 patients.The proportion achieving response (defined ≥20% improvement Positive Negative Syndrome Scale [PANSS] total score...
Schizophrenia is a serious mental disorder affecting approximately 29 million people worldwide. The ideal treatment and care of patients with schizophrenia should be provided by multidisciplinary 'team' involving psychiatrists, nurses other healthcare professionals, together carers patients. In light the key role play in schizophrenia, present survey was designed to assess opinions family members friends across Europe ascertain their attitudes towards illness, medication adherence...
It has been estimated that as many two thirds of patients with schizophrenia are unable to perform basic personal and social roles or activities. Occupational functioning functioning, well independent living, considered core domains patient functioning. Improvement in also recognized an important treatment goal guidelines outcome by regulatory agencies. Nevertheless, information is lacking on how these aspects being psychiatrists across the world they assessed managed. The ‘Europe, Middle...
Poor adherence to antipsychotic treatment is a widespread problem within schizophrenia therapy with serious consequences including increased risks of relapse and rehospitalization. Mounting evidence supports the key roles that nurses play in monitoring patient progress facilitating long-term adherence. The Adherencia Terapéutica en la Esquizofrenia (ADHES) nurses' survey was designed assess opinions on causes management partial/nonadherence medication.A questionnaire-based cross-sectional...
Long-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia. This study aimed to explore the safety, tolerability, and treatment response of paliperidone palmitate once-monthly non-acute but symptomatic adult switched from previously unsuccessful monotherapy frequently used atypical antipsychotics. was a post hoc analysis prospective, interventional, single-arm, international, multicenter, open-label, 6-month study. The (N = 472)...
Two open-label studies assessed pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy for paliperidone immediate-release 1mg (IR; Study 1) extended-release 6mg (ER; 2). Blood was collected pre-dose ≤24h (Study 1, n=3) ≤48h 2, n=4). Striatal binding measured using PET 11C-raclopride post-dose at 2.5h 22h 46h (predicted Cmax; Frontal cortex [11C]M100,907 ≥1 week 4.5h (Cmax). The apparent dissociation constant (KDapp=plasma concentration which 50% of target is occupied)...
This study aimed to establish the absorption, metabolism and excretion of paliperidone. 5 male healthy subjects received a single oral dose 14C-paliperidone 1mg, among them 2 poor 3 extensive metabolizers for cytochrome P450 2D6-mediated dextromethorphan O-demethylation. Drug metabolite levels were analyzed using LC-MS/MS in urine, feces, blood plasma collected pre-dose up 1 week post-dose. post-dose, 88.4–93.8% (mean 91.1%) radioactivity was excreted: 77.1–87.1% 79.6%) urine; 6.8–14.4%...
To compare clinical and health-related quality of life (HRQoL) outcomes between children adolescents with ADHD treated OROS® MPH, using data from two large similarly-designed multicenter, prospective, open-label, single-arm, non-interventional studies.Pooled analysis (42603ATT4037, 42603 - ATT 4001) including patients (6 to 18 years) a confirmed diagnosis ADHD. Patients were MPH for 12 weeks; symptoms, functioning, HRQoL, safety tolerability parameters assessed.822 (583 [6-12 years], 239...
Background: Long-acting antipsychotic therapy may be best suited for patients in the early stage of schizophrenia, when most can done before disease progression associated with poor adherence occurs. We explored patterns use once-monthly paliperidone palmitate (PP1M), concomitant medication use, hospitalization, and clinical outcomes adult, newly diagnosed schizophrenia receiving continuous treatment PP1M at least 12 months. Methods: This was an international, multicenter, exploratory,...
Objective:To document prescribing patterns in clinical practice and assess long-term outcomes related to initiation of paliperidone ER other oral antipsychotics among patients with schizophrenia a naturalistic setting.Research design methods:An international, non-interventional, study adult (≥18 years) schizophrenia. Patients were assigned the relevant treatment group (paliperidone or ‘all antipsychotics’) after switching to, initiating, antipsychotic treatment. Retrospective 12 month data...
Background: The negative symptoms of schizophrenia are generally harder to recognize, more difficult treat than positive symptoms, and have a significant impact on patient functioning overall outcomes. Treatment with aripiprazole may be associated benefits given its partial agonism the dopamine D 2 receptor. aim this subanalysis was explore flexibly dosed, long-acting paliperidone palmitate once monthly (PP1M) depressive disorganized thoughts, anxiety, extrapyramidal in nonacute adult...
Partial or non-adherence in patients with schizophrenia is common and increases the risk of relapse. This study explored safety, tolerability treatment outcomes hospitalised for an exacerbation initiated on maintenance once-monthly paliperidone palmitate (PP1M).A 6-week, observational cohort PP1M within 3 weeks after hospital admission.Overall, 367 were documented, 85.8% paranoid subtype. Mean time from admission to initiation was 9.4 ± 7.7 days. Treatment-emergent adverse events reported by...
Study evaluated paliperidone extended release (ER) in delaying recurrence of schizophrenia symptoms. 530 patients entered an 8-week run-in phase, receiving open-label, flexible ER (3–15mg once daily; starting dose 9mg). Patients achieving protocol-specified symptomatic control during the last 2 weeks a 6-week open-label stabilization phase (n=312). remaining stable double-blind (DB) (n=207). Time to first event DB, rate events, change PANSS total score, TEAEs and SAEs were assessed....
This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European non-European patients with schizophrenia.In this DB, parallel-group study, adult (18-70 years) schizophrenia (per DSM-IV-TR) having Positive Negative Syndrome Scale (PANSS) total score between 70 120; previously stabilized on PP1M were enrolled. The had 4 phases: screening (3 weeks), open-label...
Introduction Little is known about patient characteristics and rehospitalization in newly diagnosed patients with schizophrenia treated long-acting antipsychotics. Objectives To retrospectively explore hospitalizations, drug utilization clinical outcomes from medical records of young, during the first 12 months treatment once-monthly paliperidone palmitate (PP). Methods International, multicenter, retrospective, observational study. Outcomes presented are characteristics, reason for PP...